Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Do Hedge Funds Love Medgenics Inc (MDGN)?

Page 1 of 2

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and aim at delivering attractive risk-adjusted returns rather than following the ups and downs of equity markets, hoping that they will outperform the broader market. Our research shows that hedge funds do have great stock picking skills, so let’s take a glance at the smart money sentiment towards Medgenics Inc (NYSEMKT:MDGN).

Medgenics Inc (NYSEMKT:MDGN) shares haven’t seen a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged. The stock was in 7 hedge funds’ portfolios at the end of the third quarter of 2015. At the end of this article we will also compare MDGN to other stocks, including JAKKS Pacific, Inc. (NASDAQ:JAKK), Calamos Asset Management, Inc (NASDAQ:CLMS), and Medley Management Inc (NYSE:MDLY) to get a better sense of its popularity.

Follow Medgenics Inc. (NYSEMKT:MDGN)
Trade (NYSEMKT:MDGN) Now!

Today there are a multitude of gauges stock traders use to grade stocks. A couple of the most under-the-radar gauges are hedge fund and insider trading interest. We have shown that, historically, those who follow the top picks of the best money managers can trounce their index-focused peers by a solid amount (see the details here).

Keeping this in mind, let’s go over the fresh action regarding Medgenics Inc (NYSEMKT:MDGN).

Hedge fund activity in Medgenics Inc (NYSEMKT:MDGN)

At Q3’s end, a total of 7 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 0% from the second quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were boosting their holdings meaningfully (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, Kevin Kotler’s Broadfin Capital has the biggest position in Medgenics Inc (NYSEMKT:MDGN), worth close to $12.1 million, accounting for 0.7% of its total 13F portfolio. The second most bullish fund manager is Opaleye Management, managed by James A. Silverman, which holds an $8.3 million position; 4.1% of its 13F portfolio is allocated to the stock. Other hedge funds and institutional investors that hold long positions contain Hal Mintz’s Sabby Capital, Daniel Gold’s QVT Financial and Anand Parekh’s Alyeska Investment Group.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!